Biogen Stock Price, News & Analysis (NASDAQ:BIIB)

$327.34 -0.69 (-0.21 %)
(As of 12/12/2017 03:15 PM ET)
Previous Close$328.03
Today's Range$323.84 - $327.63
52-Week Range$244.28 - $348.84
Volume452,983 shs
Average Volume1.48 million shs
Market Capitalization$68.89 billion
P/E Ratio15.09
Dividend YieldN/A
Beta0.73

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000

Debt

Debt-to-Equity Ratio0.46%
Current Ratio2.19%
Quick Ratio1.90%

Price-To-Earnings

Trailing P/E Ratio15.09
Forward P/E Ratio14.86
P/E Growth2.03

Sales & Book Value

Annual Sales$11.45 billion
Price / Sales6.05
Cash Flow$23.75 per share
Price / Cash13.78
Book Value$56.18 per share
Price / Book5.83

Profitability

Trailing EPS$16.31
Net Income$3.70 billion
Net Margins29.44%
Return on Equity38.51%
Return on Assets20.80%

Miscellaneous

Employees7,400
Outstanding Shares211,480,000

Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings results on Tuesday, October, 24th. The biotechnology company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.70 by $0.61. The biotechnology company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The company's revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the business posted $5.19 earnings per share. View Biogen's Earnings History.

When will Biogen make its next earnings announcement?

Biogen is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Biogen.

Where is Biogen's stock going? Where will Biogen's stock price be in 2017?

28 analysts have issued twelve-month target prices for Biogen's stock. Their predictions range from $279.00 to $415.00. On average, they expect Biogen's stock price to reach $345.54 in the next twelve months. View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • 1. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
  • 2. Citigroup Inc. analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
  • 3. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
  • 4. Mizuho analysts commented, "We looked through early Spinraza data to draw as close to apples to apples comparison as possible. Here is a chart we found (from an old BIIB deck), which shows Spinraza increases SMN protein by ~2.7x." (10/2/2017)
  • 5. Cowen Inc analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board (Age 68)
  • Michel Vounatsos, Chief Executive Officer, Director (Age 55)
  • Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance (Age 51)
  • Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President (Age 49)
  • Kenneth A. Di Pietro, Executive Vice President - Human Resources (Age 58)
  • Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary (Age 60)
  • Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development (Age 48)
  • Chirfi Guindo, Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
  • Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs (Age 54)
  • Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations (Age 51)

Who owns Biogen stock?

Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.10%), Ameriprise Financial Inc. (1.09%), Jackson Square Partners LLC (1.06%), Janus Henderson Group PLC (0.68%), Legal & General Group Plc (0.52%) and American Century Companies Inc. (0.43%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., American Century Companies Inc., Swedbank, Prudential Financial Inc., Manning & Napier Advisors LLC, Westfield Capital Management Co. LP, AXA and First Quadrant L P CA. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Bank of New York Mellon Corp, Assenagon Asset Management S.A., Jackson Square Partners LLC, Schroder Investment Management Group, State of Wisconsin Investment Board, Argent Capital Management LLC and Nomura Asset Management Co. Ltd.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of Biogen stock can currently be purchased for approximately $327.34.

How big of a company is Biogen?

Biogen has a market capitalization of $68.89 billion and generates $11.45 billion in revenue each year. The biotechnology company earns $3.70 billion in net income (profit) each year or $16.31 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.


MarketBeat Community Rating for Biogen (BIIB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,176 (Vote Outperform)
Underperform Votes:  701 (Vote Underperform)
Total Votes:  1,877
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biogen (NASDAQ:BIIB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.662.672.652.58
Ratings Breakdown: 0 Sell Rating(s)
11 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
13 Buy Rating(s)
2 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $345.54$342.62$335.50$330.39
Price Target Upside: 8.87% upside9.61% upside1.76% upside30.40% upside

Biogen (NASDAQ:BIIB) Consensus Price Target History

Price Target History for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017Royal Bank of CanadaReiterated RatingHold$321.00LowView Rating Details
12/4/2017OppenheimerSet Price TargetBuy$350.00LowView Rating Details
11/27/2017CowenReiterated RatingBuy$338.00LowView Rating Details
11/27/2017BMO Capital MarketsReiterated RatingBuy$385.00LowView Rating Details
11/27/2017J P Morgan Chase & CoSet Price TargetBuy$378.00MediumView Rating Details
11/28/2017Sanford C. BernsteinSet Price TargetBuy$310.00 -> $318.00MediumView Rating Details
11/27/2017MizuhoSet Price TargetBuy$400.00MediumView Rating Details
10/27/2017Canaccord GenuityInitiated CoverageHold -> Hold$340.00N/AView Rating Details
10/25/2017HC WainwrightReiterated RatingBuy$340.00N/AView Rating Details
10/24/2017SunTrust BanksReiterated RatingBuy$354.00N/AView Rating Details
10/24/2017Cantor FitzgeraldReiterated RatingHold$279.00N/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$402.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$390.00N/AView Rating Details
10/23/2017CitigroupDowngradeBuy -> NeutralN/AView Rating Details
10/18/2017Bank of AmericaBoost Price TargetBuy$358.00 -> $365.00N/AView Rating Details
10/17/2017Morgan StanleyReiterated RatingBuyN/AView Rating Details
10/17/2017Stifel NicolausUpgradeHold -> Buy$300.00 -> $415.00N/AView Rating Details
9/21/2017Raymond James FinancialDowngradeStrong-Buy -> Market Perform$244.28 -> $319.00LowView Rating Details
8/25/2017Robert W. BairdReiterated RatingHold$290.00LowView Rating Details
8/16/2017Goldman Sachs GroupUpgradeBuy -> Conviction-Buy$338.00LowView Rating Details
7/26/2017Deutsche BankReiterated RatingBuy$315.00 -> $319.00LowView Rating Details
7/26/2017Leerink SwannReiterated RatingMarket Perform$304.00 -> $338.00HighView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$300.00LowView Rating Details
7/11/2017Jefferies GroupReiterated RatingHold -> Hold$310.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
4/23/2017BarclaysReiterated RatingOverweight$380.00 -> $360.00MediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Biogen (NASDAQ:BIIB) Earnings History and Estimates Chart

Earnings by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ BIIB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018$5.54N/AView Earnings Details
10/24/2017Q3 2017$5.70$6.31$3.05 billion$3.08 billionViewN/AView Earnings Details
7/25/2017Q2 2017$4.36$5.04$2.81 billion$3.08 billionViewN/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.73 billion$2.81 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Biogen (NASDAQ:BIIB) Earnings Estimates

2017 EPS Consensus Estimate: $20.32
2018 EPS Consensus Estimate: $24.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$4.47$5.03$4.75
Q2 20173$3.92$4.11$4.04
Q3 20174$5.69$6.16$5.92
Q4 20175$5.12$6.04$5.61
Q1 20183$5.77$6.08$5.94
Q2 20184$5.93$6.35$6.14
Q3 20183$6.04$6.24$6.17
Q4 20183$6.12$6.23$6.17
Q1 20191$6.30$6.30$6.30
Q2 20191$6.53$6.53$6.53
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biogen (NASDAQ:BIIB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 88.30%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ BIIB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2017Alexander J DennerDirectorBuy30,000$317.36$9,520,800.00View SEC Filing  
7/25/2017Susan H AlexanderEVPSell4,974$290.01$1,442,509.74View SEC Filing  
7/19/2017Susan H AlexanderEVPSell7,758$285.00$2,211,030.00View SEC Filing  
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.04View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.00View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.48View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.05View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.50View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.28View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.00View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.00View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biogen (NASDAQ BIIB) News Headlines

Source:
DateHeadline
 Brokerages Expect Biogen Inc (BIIB) Will Post Quarterly Sales of $3.05 Billion Brokerages Expect Biogen Inc (BIIB) Will Post Quarterly Sales of $3.05 Billion
www.americanbankingnews.com - December 12 at 2:52 AM
Biogen Inc (BIIB) Receives Consensus Rating of "Buy" from BrokeragesBiogen Inc (BIIB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 11 at 4:32 PM
Vapid Sales Growth Penalize Biogen (BIIB) RatingVapid Sales Growth Penalize Biogen (BIIB) Rating
investorplace.com - December 11 at 3:49 PM
Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : December 6, 2017Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : December 6, 2017
finance.yahoo.com - December 6 at 3:18 PM
Biogen vet launches cancer drug startup with $50M from GV, othersBiogen vet launches cancer drug startup with $50M from GV, others
finance.yahoo.com - December 6 at 6:46 AM
Biogen (BIIB) PT Set at $350.00 by OppenheimerBiogen (BIIB) PT Set at $350.00 by Oppenheimer
www.americanbankingnews.com - December 5 at 6:34 PM
ETFs with exposure to Biogen, Inc. : December 5, 2017ETFs with exposure to Biogen, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:19 PM
Biogen (BIIB) Price Target Raised to $321.00 at Royal Bank Of CanadaBiogen (BIIB) Price Target Raised to $321.00 at Royal Bank Of Canada
www.americanbankingnews.com - December 5 at 12:38 PM
Biogen (BIIB) a Hold on Uninspiring Sales Growth - Investorplace.comBiogen (BIIB) a Hold on Uninspiring Sales Growth - Investorplace.com
investorplace.com - December 5 at 6:20 AM
Biogen (BIIB) a Hold on Uninspiring Sales GrowthBiogen (BIIB) a Hold on Uninspiring Sales Growth
investorplace.com - December 4 at 3:39 PM
[$$] Icahn Proteges Big Biotech Buys: Biogen, Medicines[$$] Icahn Protege's Big Biotech Buys: Biogen, Medicines
finance.yahoo.com - December 4 at 3:18 PM
Insider Buying: Biogen Inc. (BIIB) Director Buys $9,520,800.00 in StockInsider Buying: Biogen Inc. (BIIB) Director Buys $9,520,800.00 in Stock
www.americanbankingnews.com - November 30 at 10:30 AM
Biogen Inc. to Post FY2017 Earnings of $22.33 Per Share, William Blair Forecasts (BIIB)Biogen Inc. to Post FY2017 Earnings of $22.33 Per Share, William Blair Forecasts (BIIB)
www.americanbankingnews.com - November 29 at 9:08 AM
Biogen (BIIB) Given a $400.00 Price Target by Mizuho AnalystsBiogen (BIIB) Given a $400.00 Price Target by Mizuho Analysts
www.americanbankingnews.com - November 28 at 8:36 PM
Biogen (BIIB) Stock Rating Reaffirmed by CowenBiogen (BIIB) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - November 28 at 1:36 PM
Biogens (BIIB) "Buy" Rating Reaffirmed at BMO Capital MarketsBiogen's (BIIB) "Buy" Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - November 28 at 1:36 PM
J P Morgan Chase & Co Analysts Give Biogen (BIIB) a $378.00 Price TargetJ P Morgan Chase & Co Analysts Give Biogen (BIIB) a $378.00 Price Target
www.americanbankingnews.com - November 28 at 11:20 AM
Q4 2017 EPS Estimates for Biogen Inc. Reduced by William Blair (BIIB)Q4 2017 EPS Estimates for Biogen Inc. Reduced by William Blair (BIIB)
www.americanbankingnews.com - November 28 at 11:18 AM
Biogens (BIIB) Outperform Rating Reaffirmed at Sanford C. BernsteinBiogen's (BIIB) Outperform Rating Reaffirmed at Sanford C. Bernstein
www.americanbankingnews.com - November 28 at 9:50 AM
Oppenheimer Weighs in on Biogen Inc.s FY2017 Earnings (BIIB)Oppenheimer Weighs in on Biogen Inc.'s FY2017 Earnings (BIIB)
www.americanbankingnews.com - November 28 at 6:36 AM
Alkermes Could Win Big With New Biogen PartnershipAlkermes Could Win Big With New Biogen Partnership
247wallst.com - November 27 at 6:33 PM
Biogen Inc. Buys Its Way Out of CompetitionBiogen Inc. Buys Its Way Out of Competition
finance.yahoo.com - November 27 at 6:33 PM
Biogen (BIIB) a Hold on Poor Sales GrowthBiogen (BIIB) a Hold on Poor Sales Growth
investorplace.com - November 27 at 3:47 PM
 Analysts Anticipate Biogen Inc. (BIIB) Will Announce Quarterly Sales of $3.05 Billion Analysts Anticipate Biogen Inc. (BIIB) Will Announce Quarterly Sales of $3.05 Billion
www.americanbankingnews.com - November 24 at 2:34 AM
 Brokerages Anticipate Biogen Inc. (BIIB) to Post $5.55 EPS Brokerages Anticipate Biogen Inc. (BIIB) to Post $5.55 EPS
www.americanbankingnews.com - November 22 at 11:10 PM
Biogen Inc. (BIIB) Given Buy Rating at Oppenheimer Holdings, Inc.Biogen Inc. (BIIB) Given Buy Rating at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 22 at 1:44 PM
Biogen (BIIB) Names Jeff Capello as EVP and Chief Financial Officer - StreetInsider.comBiogen (BIIB) Names Jeff Capello as EVP and Chief Financial Officer - StreetInsider.com
www.streetinsider.com - November 21 at 3:28 PM
Sales Growth Hamper Biogen (BIIB) Rating - Investorplace.comSales Growth Hamper Biogen (BIIB) Rating - Investorplace.com
investorplace.com - November 21 at 3:28 PM
Bet on Biogen Inc for Easy Profits Into the New Year - Investorplace.comBet on Biogen Inc for Easy Profits Into the New Year - Investorplace.com
investorplace.com - November 21 at 3:28 PM
Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial OfficerBiogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
finance.yahoo.com - November 21 at 3:28 PM
Biogen taps former Boston Scientific exec as next CFOBiogen taps former Boston Scientific exec as next CFO
finance.yahoo.com - November 21 at 3:28 PM
Bet on Biogen Inc for Easy Profits Into the New YearBet on Biogen Inc for Easy Profits Into the New Year
investorplace.com - November 21 at 9:48 AM
Sales Growth Hamper Biogen (BIIB) RatingSales Growth Hamper Biogen (BIIB) Rating
investorplace.com - November 20 at 4:21 PM
Better Buy: Biogen Inc. vs. Gilead SciencesBetter Buy: Biogen Inc. vs. Gilead Sciences
www.fool.com - November 18 at 10:41 AM
Biogen Inc. (BIIB) Receives Consensus Recommendation of "Buy" from BrokeragesBiogen Inc. (BIIB) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 16 at 2:02 PM
If An Alzheimers Drug Succeeds, Could Our Health System Handle It?If An Alzheimer's Drug Succeeds, Could Our Health System Handle It?
finance.yahoo.com - November 16 at 12:00 PM
Biogen (BIIB) a Hold on Feeble Quant Score - Investorplace.comBiogen (BIIB) a Hold on Feeble Quant Score - Investorplace.com
investorplace.com - November 14 at 6:00 AM
Biogen Inc. (BIIB) Given a $400.00 Price Target by Mizuho AnalystsBiogen Inc. (BIIB) Given a $400.00 Price Target by Mizuho Analysts
www.americanbankingnews.com - November 13 at 5:12 PM
Biogen (BIIB) a Hold on Feeble Quant ScoreBiogen (BIIB) a Hold on Feeble Quant Score
investorplace.com - November 13 at 3:40 PM
Biogen Inc. (BIIB) Forecasted to Post FY2017 Earnings of $21.97 Per ShareBiogen Inc. (BIIB) Forecasted to Post FY2017 Earnings of $21.97 Per Share
www.americanbankingnews.com - November 13 at 3:58 AM
Brokers Set Expectations for Biogen Inc.s FY2021 Earnings (BIIB)Brokers Set Expectations for Biogen Inc.'s FY2021 Earnings (BIIB)
www.americanbankingnews.com - November 10 at 8:11 PM
BMO Capital Markets Increases Biogen Inc. (BIIB) Price Target to $386.00BMO Capital Markets Increases Biogen Inc. (BIIB) Price Target to $386.00
www.americanbankingnews.com - November 6 at 9:43 PM
BMO Capital Markets Increases Biogen Inc. (BIIB) Price Target to $386.00BMO Capital Markets Increases Biogen Inc. (BIIB) Price Target to $386.00
www.americanbankingnews.com - November 6 at 9:43 PM
Vapid Sales Growth Hamper Biogen (BIIB) RatingVapid Sales Growth Hamper Biogen (BIIB) Rating
investorplace.com - November 6 at 5:09 PM
Optimer Pharmaceuticals (OPTR) and Biogen (BIIB) Head-To-Head ReviewOptimer Pharmaceuticals (OPTR) and Biogen (BIIB) Head-To-Head Review
www.americanbankingnews.com - November 5 at 5:26 AM
Biogen (BIIB) & Syndax Pharmaceuticals (SNDX) Head to Head AnalysisBiogen (BIIB) & Syndax Pharmaceuticals (SNDX) Head to Head Analysis
www.americanbankingnews.com - November 4 at 5:46 PM
Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment AducanumabBiogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
finance.yahoo.com - November 2 at 10:11 PM
Top Analyst Reports for Microsoft, Chevron & IntelTop Analyst Reports for Microsoft, Chevron & Intel
finance.yahoo.com - October 31 at 10:43 PM
Sales Growth Restricts Biogen (BIIB) RatingSales Growth Restricts Biogen (BIIB) Rating
investorplace.com - October 30 at 3:10 PM
Biogen Inc. to Post FY2020 Earnings of $26.70 Per Share, SunTrust Banks Forecasts (BIIB)Biogen Inc. to Post FY2020 Earnings of $26.70 Per Share, SunTrust Banks Forecasts (BIIB)
www.americanbankingnews.com - October 27 at 7:46 PM

SEC Filings

Biogen (NASDAQ:BIIB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biogen (NASDAQ BIIB) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.